# Revolution Medicines Receives Breakthrough Therapy Designation for Daraxonrasib in RAS Mutant Non-Small Cell Lung Cancer

> fda · REPORTED · 2026-08-05

In addition to its pancreatic cancer approval, the FDA granted Revolution Medicines Breakthrough Therapy Designation for daraxonrasib for patients with previously treated metastatic RAS mutant non-small cell lung cancer, further expanding the potential reach of its RAS inhibitor platform across multiple tumor types.

About Revolution Medicines: Revolution Medicines is developing a portfolio of oral RAS inhibitors targeting RAS-addicted cancers across multiple tumor types, with daraxonrasib as the lead asset.

- Company: Revolution Medicines
- Sector: oncology
- Primary source: https://www.sec.gov/Archives/edgar/data/0001628171/000119312526335039/rvmd-ex99_1.htm

---
Source: MedFuel Intel news monitor. Verification tier: REPORTED. Informational only, not investment advice. Corrections: media@medfuelinc.com.